OTCMKTS:VEGPFVectura Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vectura Group PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.22 0.00 (0.00 %) (As of 07/7/2020 04:00 PM ET) Add Compare Share Today's Range$1.22Now: $1.22▼$1.2250-Day Range$0.80MA: $0.97▼$1.2252-Week Range$0.80Now: $1.22▼$1.22VolumeN/AAverage VolumeN/AMarket Capitalization$737.20 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsHeadlinesSocial Media Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Vectura Group. Previous Next 2.3 Community Rank Outperform VotesVectura Group has received 40 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVectura Group has received 47 “underperform” votes. (Add your “underperform” vote.)Community SentimentVectura Group has received 54.02% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vectura Group and other stocks. Vote “Outperform” if you believe VEGPF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VEGPF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVectura Group does not currently pay a dividend.Dividend GrowthVectura Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vectura Group insiders have not sold or bought any company stock. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vectura Group are expected to grow by 200.00% in the coming year, from $0.06 to $0.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vectura Group is -30.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vectura Group is -30.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVectura Group has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.84 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:VEGPF Previous Symbol CUSIPN/A CIKN/A Webwww.vectura.com Phone44-0-12-4966-7700Debt Debt-to-Equity Ratio0.02 Current Ratio2.28 Quick Ratio1.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio20.33 P/E GrowthN/A Sales & Book Value Annual Sales$227.68 million Price / Sales3.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book1.37Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees478 Outstanding Shares604,260,000Market Cap$737.20 million Next Earnings DateN/A OptionableNot Optionable OTC:VEGPF Rates by TradingView Receive VEGPF News and Ratings via Email Sign-up to receive the latest news and ratings for VEGPF and its competitors with MarketBeat's FREE daily newsletter. Vectura Group (OTCMKTS:VEGPF) Frequently Asked Questions How has Vectura Group's stock been impacted by COVID-19 (Coronavirus)? Vectura Group's stock was trading at $1.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VEGPF stock has increased by 8.9% and is now trading at $1.22. View which stocks have been most impacted by Coronavirus. Has Vectura Group been receiving favorable news coverage? News articles about VEGPF stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vectura Group earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Vectura Group. Who are some of Vectura Group's key competitors? Some companies that are related to Vectura Group include Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Myrexis (MYRX), NeuroVive Pharmaceutical (NEVPF), Pivotal Therapeutics (PVTTF), Poniard Pharmaceuticals (PARD) and Skystar Bio-Pharmaceutical (SKBI). View all competitors. Who are Vectura Group's key executives? Vectura Group's management team includes the following people: Mr. James Ward-Lilley, CEO & Exec. Director (Age 54)Mr. Paul Fry, CFO & Exec. DirectorMr. Anthony Fitzpatrick, Exec. VP of OperationsElizabeth Knowles, VP of Investor RelationsMr. John Murphy, Gen. Counsel & Company Sec. (Age 66) What is Vectura Group's stock symbol? Vectura Group trades on the OTCMKTS under the ticker symbol "VEGPF." How do I buy shares of Vectura Group? Shares of VEGPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vectura Group's stock price today? One share of VEGPF stock can currently be purchased for approximately $1.22. How big of a company is Vectura Group? Vectura Group has a market capitalization of $737.20 million and generates $227.68 million in revenue each year. The company earns $-28,220,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Vectura Group employs 478 workers across the globe. What is Vectura Group's official website? The official website for Vectura Group is www.vectura.com. How can I contact Vectura Group? Vectura Group's mailing address is One Prospect West, Wiltshire X0, SN14 6FH. The company can be reached via phone at 44-0-12-4966-7700 or via email at [email protected] This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
